众生药业股价微跌1.01% 创新药RAY0221进入临床前研究

Core Insights - The stock price of Zhongsheng Pharmaceutical closed at 22.56 yuan on August 21, 2025, down by 0.23 yuan, representing a decline of 1.01% [1] - The company is focused on the research and development of traditional Chinese medicine and innovative drugs, with a recent emphasis on the innovative drug RAY0221, which is intended for the treatment of diabetes, obesity, and non-alcoholic fatty liver disease [1] - RAY0221 is currently in the preclinical research stage, and the company plans to advance its development as scheduled [1] - On August 21, the net outflow of main funds was 61.98 million yuan, accounting for 0.36% of the circulating market value, while the cumulative net inflow over the past five trading days was 109 million yuan, representing 0.64% of the circulating market value [1] Financial Performance - The trading volume on August 21 was 848 million yuan, with a turnover rate of 4.92% [1]